Royalty Pharma Balance Sheet Health

Financial Health criteria checks 4/6

Royalty Pharma has a total shareholder equity of $10.1B and total debt of $6.1B, which brings its debt-to-equity ratio to 60.8%. Its total assets and total liabilities are $16.4B and $6.3B respectively. Royalty Pharma's EBIT is $1.5B making its interest coverage ratio 13. It has cash and short-term investments of $495.3M.

Key information

60.8%

Debt to equity ratio

US$6.14b

Debt

Interest coverage ratio13x
CashUS$495.31m
EquityUS$10.08b
Total liabilitiesUS$6.30b
Total assetsUS$16.38b

Recent financial health updates

No updates

Recent updates

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22
Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26
Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25
The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma Offers A Unique Long-Term Investment Opportunity

Mar 01

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Jan 25
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Jan 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19

Royalty Pharma: A Pharma-Like Company Without The Same Risks

Dec 27

Financial Position Analysis

Short Term Liabilities: RPRX's short term assets ($1.3B) exceed its short term liabilities ($161.4M).

Long Term Liabilities: RPRX's short term assets ($1.3B) do not cover its long term liabilities ($6.1B).


Debt to Equity History and Analysis

Debt Level: RPRX's net debt to equity ratio (55.9%) is considered high.

Reducing Debt: RPRX's debt to equity ratio has reduced from 143.2% to 60.8% over the past 5 years.

Debt Coverage: RPRX's debt is well covered by operating cash flow (48.7%).

Interest Coverage: RPRX's interest payments on its debt are well covered by EBIT (13x coverage).


Balance Sheet


Discover healthy companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.